MyLife Diabetes Care, CamDiab and Dexcom today announced the integration of the G7 continuous glucose monitor (CGM) into the ...

～高精度で小型化、起動時間を短縮し、使いやすさの向上を目指したデバイス～ デクスコムジャパン合同会社（本社：東京都目黒区、日本法人社長 浅野 元）は本日、リアルタイムCGM「Dexcom G7 ...

「Dexcom G7」は、糖尿病のある方の日常の血糖マネジメントを容易にする新しいリアルタイムCGMで、この度、革新的な前製品（Dexcom G6）を、より小さく、使いやすく、かつ手ごろな価格でリデザインした点が高く評価され、2024年度グッドデザイン賞を受賞し ...

In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and ...

The FDA is warning about two lots of defective Dexcom glucose monitors that were stolen and resold. These devices are at risk ...

Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks.

People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on sensors.

The diabetes tech firm has identified two lots of G7 sensors that have been stolen, sold and used by customers.

May 26 (Reuters) - Medical device maker Dexcom said on Tuesday some of its glucose sensors slated for destruction were ...

DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting ...

Dexcom (Nasdaq:DXCM) announced today that third parties stole and sold certain G7 continuous glucose monitor (CGM) lots ...